These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32344449)

  • 1. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
    Al-Kofahi M; Jacobson P; Boulware DR; Matas A; Kandaswamy R; Jaber MM; Rajasingham R; Young JH; Nicol MR
    Clin Pharmacol Ther; 2020 Oct; 108(4):766-769. PubMed ID: 32344449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
    Kauv J; Lê MP; Veyrier M; Le Hingrat Q; Visseaux B; Massias L; Chauveheid MP; Descamps D; Ghosn J; Peytavin G
    J Antimicrob Chemother; 2020 Sep; 75(9):2706-2707. PubMed ID: 32457980
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
    Mehta S; Bhandari S; Mehta S
    J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    Rathi S; Ish P; Kalantri A; Kalantri S
    Lancet Infect Dis; 2020 Oct; 20(10):1118-1119. PubMed ID: 32311324
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
    Ahn BY; Kang CK; Seo JD; Choe PG; Song SH; Park WB; Park SW; Kim NJ; Oh MD
    J Korean Med Sci; 2020 Jun; 35(24):e231. PubMed ID: 32567262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
    Boulware DR; Pullen MF; Bangdiwala AS; Pastick KA; Lofgren SM; Okafor EC; Skipper CP; Nascene AA; Nicol MR; Abassi M; Engen NW; Cheng MP; LaBar D; Lother SA; MacKenzie LJ; Drobot G; Marten N; Zarychanski R; Kelly LE; Schwartz IS; McDonald EG; Rajasingham R; Lee TC; Hullsiek KH
    N Engl J Med; 2020 Aug; 383(6):517-525. PubMed ID: 32492293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
    Koc G; Odabasi Z; Tan E
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):60-62. PubMed ID: 32833728
    [No Abstract]   [Full Text] [Related]  

  • 12. US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
    Shehab N; Lovegrove M; Budnitz DS
    JAMA Intern Med; 2020 Oct; 180(10):1384-1386. PubMed ID: 32628242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Time for Post-Exposure Prophylaxis?
    Gentile I; Maraolo AE; Piscitelli P; Colao A
    Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32512873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
    Sivapalan P; Ulrik CS; Lappere TS; Eklöf JV; Shaker SB; Bødtger UCS; Browatzki A; Meyer CN; Weinreich UM; Laursen CB; Biering-Sørensen T; Knop FK; Lundgren JD; Jensen JS
    Trials; 2020 Oct; 21(1):867. PubMed ID: 33081817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
    Pirjani R; Soori T; Dehpour AR; Sepidarkish M; Moini A; Shizarpour A; Mohammad Jafari R
    Trials; 2020 Jun; 21(1):467. PubMed ID: 32493447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
    Kara E; Demirkan K; Unal S
    Int J Antimicrob Agents; 2020 Sep; 56(3):106123. PubMed ID: 32738307
    [No Abstract]   [Full Text] [Related]  

  • 17. Can prophylactic drugs keep fragile health systems running?
    Kupferschmidt K
    Science; 2020 Apr; 368(6487):118-119. PubMed ID: 32273446
    [No Abstract]   [Full Text] [Related]  

  • 18. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
    Lee SH; Son H; Peck KR
    Int J Antimicrob Agents; 2020 Jun; 55(6):105988. PubMed ID: 32305587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
    Lê MP; Peiffer-Smadja N; Guedj J; Néant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G
    J Antimicrob Chemother; 2020 Sep; 75(9):2376-2380. PubMed ID: 32473020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed.
    Tahiri Joutei Hassani R; Bennis A
    J Infect Public Health; 2020 Jun; 13(6):865-867. PubMed ID: 32451259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.